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Magnesium in Head and Neck Cancer 
Is it a possible Biomarker for Tumor Treatment? 
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Abstract—We investigated the hypothesis that patients with advanced head and neck cancer exhibit a decreased serum 
concentration of magnesium compared to the normal population. In July 2013 we measured the magnesium serum 
concentration of 18 patients with squamous cell carcinoma of the head and neck region. The control group consisted of 17 
patients received tonsillectomy during the same period. Overall 14/18 patients with cancer have had Magnesium serum 
concentrations < 0.80 mmol/l (78%). The control group showed only two patients (12%) with serum levels below the cut 
off. This small controlled study supports the hypothesis that decreased Magnesium serum concentrations are typical for 
patients with advanced head and neck cancer. We could not show, that hypomagnesaemia is prognostic biomarker in head 
and neck cancer treatment. 
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